Advertisements

Volfenac Retard

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Volfenac Retard

Property Description
Active ingredient Diclofenac Sodium
Form Prolonged-Release Tablet (Sustained-Release)
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Origin Synthetic (Phenylacetic Acid Derivative)
General purpose Alleviation of pain and inflammation

What Type of Medicine is Volfenac Retard?

Volfenac Retard is a potent, prescription-only medication whose active ingredient is Diclofenac, a substance formally classified as a core Non-Steroidal Anti-Inflammatory Drug (NSAID). This medicine is a synthetic compound, specifically a phenylacetic acid derivative, which is chemically distinct from other major NSAID groups. Diclofenac is recognized for its inhibitory effect on the biochemical pathways responsible for pain and inflammation, making it an effective agent in its class.

As a single-active ingredient product, the therapeutic focus of Volfenac Retard is entirely on the action of Diclofenac Sodium. The NSAID classification confirms that the drug’s general purpose is to provide relief by mitigating the biological processes of pain and inflammation, an action often required for chronic musculoskeletal issues.


Understanding the Prolonged-Release ('Retard') Tablet

The designation 'Retard' signifies that Volfenac Retard is formulated as an Oral Prolonged-Release Tablet (also known as a sustained-release or extended-release form). This specialized dosage form is intentionally engineered to release the Diclofenac slowly and consistently over many hours. This sustained-release formulation is designed to provide more stable plasma concentrations compared to immediate-release versions. This consistent absorption is a key differentiating feature, allowing for symptom control over extended periods.

The primary benefit of this sustained-release formulation is the potential for consistent, long-lasting relief. By maintaining steady therapeutic levels, the prolonged-release tablet supports the continuous management of chronic stiffness and discomfort, which is useful for patients requiring continuous daily symptom mitigation.


Volfenac Retard: Its Fundamental Purpose

The fundamental purpose of Volfenac Retard is to alleviate symptoms by mitigating the core processes of pain and inflammation wherever they occur in the body. It achieves this by acting as an inhibitor of specific body chemicals, known as prostaglandins, which are responsible for triggering pain signals and local inflammatory responses, a mechanism central to all NSAIDs. By intervening in the production of these messengers, the medicine reduces swelling, heat, and discomfort. This makes the overall general benefit of Volfenac Retard the sustained reduction of both the sensation of pain and the underlying biological condition of inflammation.

Regulatory References

  1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - StatPearls - NCBI Bookshelf
Advertisements

What side effects are possible with Volfenac Retard?

Possible side effects and safety information

Official regulatory documents classify the safety profile of Volfenac Retard by System Organ Class and frequency of occurrence. The most serious risks primarily involve the cardiovascular and gastrointestinal systems.

Serious and Clinically Significant Risks

Authorities document the risk of serious, potentially fatal Arterial Thrombotic Events, including Myocardial Infarction (heart attack) and Stroke. This risk may increase with higher doses and longer duration of use. The drug is contraindicated in patients with established Congestive Heart Failure (NYHA Class II-IV), Ischaemic Heart Disease, Peripheral Arterial Disease, or Cerebrovascular Disease.

Severe Gastrointestinal (GI) adverse events are also reported, such as bleeding, ulceration, and perforation of the stomach or intestines, which can occur without warning symptoms. The elderly are at higher risk for these serious GI events.

Other serious risks include Liver (Hepatic) Injury and severe Kidney (Renal) Injury. Severe and sometimes fatal Skin Reactions (e.g., Stevens-Johnson Syndrome) and Hypersensitivity Reactions (e.g., Anaphylaxis) are also documented.

Adverse Reactions by Frequency

Adverse reactions are classified by frequency, with examples including:

  • Common: Headache, dizziness, vertigo, gastrointestinal disorders (e.g., nausea, dyspepsia, abdominal pain).
  • Rare: Hypersensitivity, somnolence, asthma, gastrointestinal haemorrhage, hepatic dysfunction.
  • Very Rare: Disorientation, visual disturbances, pancreatitis, bullous eruptions.

Safety Limitations

To minimize risks, the mandatory official safety guidance emphasizes using the lowest effective dose for the shortest duration necessary for all patients. Close medical surveillance is imperative for patients with a history of GI disorders or impaired hepatic or renal function.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This information describes the official, regulator-documented profile for an overdose of Diclofenac Sodium (the active ingredient in Volfenac Retard).


Documented Overdose Manifestations

An overdose may involve symptoms affecting multiple body systems, as documented in official prescribing information. These include gastrointestinal signs such as nausea, vomiting, epigastric pain, and gastrointestinal bleeding. Central Nervous System (CNS) symptoms may also occur, including dizziness, headache, and drowsiness. In more severe cases, acute renal failure, liver damage (hepatotoxicity), convulsions, or respiratory depression are documented severe outcomes.


Emergency Action Required

Regulatory authorities mandate that any person who has ingested a potentially toxic amount of this medicine seek immediate medical attention. Emergency services must be contacted immediately upon the occurrence of any severe effects, such as a change in consciousness or difficulty breathing.


Overdose Management

Official labeling states that no specific antidote is known for Diclofenac poisoning. Therefore, management is strictly symptomatic and supportive treatment. This may involve procedures like activated charcoal or gastric lavage if the toxic ingestion was recent. Patients require close medical observation and laboratory monitoring of vital functions, particularly renal and hepatic function, due to the risk of delayed severe effects. Patients with pre-existing kidney or liver impairment are noted to be at increased risk of severe outcomes.

Advertisements

Therapeutic Uses of Volfenac Retard

Volfenac Retard (prolonged-release Diclofenac Sodium) is commonly used across domains where additional symptomatic support is needed, relevant in contexts marked by increased discomfort or tension.

Diclofenac may be part of symptomatic management to help ease pain, tenderness, swelling, and stiffness associated with various forms of arthritis and other painful conditions.

Sustained Symptomatic Support

This medication is relevant for easing symptoms associated with conditions involving episodic or fluctuating manifestations, such as chronic inflammatory joint conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is applied across domains where additional symptomatic support is needed to help manage groups of symptoms like joint pain, swelling, and morning stiffness that may become disruptive during flare-ups.

Quick Fact: Relevance in Inflammatory Symptom Management It is applied in clinical settings that involve acute or unstable symptom patterns, such as pain from injuries like sprains, or post-procedure discomfort, and specific non-rheumatic conditions, like primary dysmenorrhea.

“The sustained action of the medicine contributes to easing the overall symptom load throughout periods of heightened discomfort.”

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Volfenac Retard (prolonged-release Diclofenac) is officially permitted for use only in adults aged 18 years and older for labeled indications. The prolonged-release formulation is not suitable for children and adolescents under 18 years, as its safety and efficacy are not established in the pediatric population.


Populations For Whom Use Is Contraindicated

The medicine is strictly contraindicated (must not be used) in patients with the following conditions:

  • Hypersensitivity or Allergy to Diclofenac, aspirin, or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) that trigger asthma, hives, or acute rhinitis.
  • Active Gastrointestinal Disease, including ulceration, bleeding, or perforation of the stomach or intestines.
  • Severe Organ Failure (Hepatic Failure or Renal Failure).
  • Established Cardiovascular Disease, including Congestive Heart Failure (NYHA II–IV), Ischemic Heart Disease, Peripheral Arterial Disease, or Cerebrovascular Disease.
  • Peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Age and Life-Stage Restrictions

  • Pregnancy (Third Trimester): Use is contraindicated due to risk of fetal harm.
  • Pregnancy (First/Second Trimester): Use is not recommended unless essential, and must be for the shortest duration possible.
  • Breastfeeding: Use is not recommended due to the potential presence of small amounts in breast milk.
  • Elderly/Frail Patients: Caution is advised, and close monitoring is required, especially regarding gastrointestinal and renal function.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes clinically significant interactions for Volfenac Retard (Diclofenac) based on regulatory documents. Consult a healthcare professional before combining medications.


Contraindicated and High-Risk Combinations

  • Other Systemic NSAIDs (including COX-2 inhibitors): Co-administration is generally contraindicated due to a significantly increased risk of serious gastrointestinal adverse events without additional therapeutic benefit.
  • Anticoagulants and Antiplatelets (e.g., Warfarin, Aspirin): Use is associated with a substantially increased risk of serious bleeding (pharmacodynamic interaction), necessitating close patient monitoring for signs of hemorrhage.

Pharmacokinetic and Pharmacodynamic Effects

Volfenac Retard may interact via multiple pathways:

  • CYP2C9 Inhibitors (e.g., Fluconazole): These agents can increase the plasma concentrations and systemic exposure of diclofenac, potentially raising the risk of adverse effects. Diclofenac may also increase the exposure of drugs metabolized by CYP2C9.
  • Diuretics, ACE Inhibitors, and ARBs: Combination may reduce the blood pressure-lowering effects of these medications and increase the risk of renal impairment, especially in elderly or volume-depleted patients (pharmacodynamic interaction).
  • Lithium and Methotrexate: Diclofenac can increase the serum concentrations of these drugs, requiring mandatory therapeutic drug monitoring to prevent toxicity.

Other Documented Interactions

Food and Alcohol: Consumption of alcohol while taking this medication may increase the risk of gastrointestinal bleeding. Taking the medication with food may delay absorption.

Advertisements

Mechanism of Action

Mechanism of Action: Target Inhibition and Cellular Cascades

Volfenac Retard primarily functions as an inhibitor of cyclooxygenase-2 (COX-2), a key enzyme in the conversion of arachidonic acid to prostanoids. The compound exhibits selectivity for COX-2 while also binding to cyclooxygenase-1 (COX-1) at high concentrations. By inhibiting these enzymes, the synthesis of prostaglandins, thromboxanes, and prostacyclins is suppressed. This pathway modulation results in a reduction of prostaglandin concentrations at sites of molecular activity.

Beyond COX inhibition, the compound modifies intracellular processes by modulating the activity of lipoxygenases and altering the concentration of unesterified arachidonic acid within leukocytes. Furthermore, it influences the signaling cascade involving matrix metalloproteinases (MMPs), enzymes implicated in the catabolism of structural matrix components in physiological systems.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Volfenac Retard

Volfenac Retard is a prolonged-release tablet formulation of Diclofenac Sodium. The correct usage of this medicine is dictated by specific instructions focusing strictly on administration and dosing.


Dosing and Administration Schedule

Instruction Detail
Route of Administration Oral (by mouth)
Standard Dosing Schedule 100 mg taken once daily.
Frequency Principle Consistent with NSAID protocol, the lowest effective dose should be used for the shortest duration possible.
Timing in Relation to Meals May be taken with or after food to minimize potential gastrointestinal discomfort, though total absorption is not significantly affected.

Procedural and Population Rules

Rule Type Specific Instruction
Handling Requirement The tablet must be swallowed whole with liquid and must not be crushed, chewed, or split to ensure the prolonged-release mechanism functions correctly.
Older Adults No routine dose adjustment is necessary, but the lowest effective dose should be used, especially in frail patients.
Renal Impairment Dosing adjustment is generally not necessary in mild-to-moderate renal dysfunction, as renal elimination is not a major pathway for the unchanged drug.
Missed Dose Rule If a dose is missed, it is recommended to take the next dose at the regularly scheduled time. Do not double the dose to make up for the skipped dose.

The official instructions establish a protocol for oral administration, where the once-daily schedule relies entirely on the tablet remaining intact. These procedural constraints, including the mandatory swallowing of the whole tablet, govern the correct use of Volfenac Retard.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Volfenac Retard

This overview describes the official research evidence for systemic diclofenac, the active ingredient in Volfenac Retard, focusing on what types of studies exist, the populations they examined, and the broad patterns of findings reported in scientific literature and regulatory summaries. Research is presented as context, not as clinical advice or a guarantee of individual outcomes.


Evidence for Use in Osteoarthritis and Rheumatoid Arthritis

The evidence base for using this medication class in conditions like Osteoarthritis (OA) and Rheumatoid Arthritis (RA) stems from Randomized Controlled Trials (RCTs) and systematic reviews. These studies were used in research exploring how symptoms change over defined time intervals. Research examined patient-reported outcomes describing perceived discomfort and shifts in physical function across study populations consisting of adults with these diagnoses.

For OA and RA, studies monitored changes in patient-reported axes related to physical discomfort and functional outcomes. Findings describe patterns observed in the studies related to measured patient-reported outcomes, but evidence contributes to the broader evidence landscape of symptom patterns and not disease modification. Long-term effects on the underlying disease are not fully established from these trials.


Study Design: Comparing Prolonged-Release vs. Standard Forms

Volfenac Retard is formulated as a prolonged-release tablet. Studies explored how the release of the active ingredient differed between this type of sustained-release formulation and the standard, immediate-release tablets. The studies monitored how the concentration of the active ingredient in the bloodstream evolved over a 24-hour period. Studies described patterns of absorption where the prolonged-release form was associated with more stable concentrations. These comparisons are relevant in trials assessing short-term or episodic symptom patterns.


What is Still Uncertain About the Research Base

Despite the extensive amount of research on this medication class, several areas remain uncertain. Follow-up durations were limited in many pivotal efficacy trials, meaning long-term effects are not fully established. Comparative evidence is lacking in some areas, particularly concerning direct, head-to-head comparisons of the prolonged-release formulation against all other therapeutic options. The evidence quality varies across studies, and data for certain groups, such as children or pregnant women, remain insufficient.

Key Studies & References Efficacy and Tolerability of Diclofenac in the Management of Osteoarthritis: A Systematic Review and Meta-analysis

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Volfenac Retard (FAQ)

Q: Why is it called 'Retard'?

A: The term 'Retard' is a pharmaceutical designation, also known as sustained-release or prolonged-release. This formulation is intentionally engineered to release the active ingredient, diclofenac, slowly and continuously over an extended period. This design is what makes it suitable for once-daily administration.

Q: What makes Volfenac Retard different from regular Volfenac (or immediate-release Diclofenac)?

A: Volfenac Retard is a prolonged-release tablet, meaning it releases the drug at a controlled, slower rate. This differs from immediate-release forms, which release the medication quickly. Official studies indicate that this controlled release helps maintain more stable concentrations of the drug in the bloodstream over time.

Q: How quickly does Volfenac Retard start to work?

A: As a prolonged-release formulation, the absorption of the active substance is deliberately delayed compared to immediate-release forms. Consequently, the initial onset of its therapeutic effect is also slower compared to standard immediate-release versions of the medication.

Q: How long does the pain relief from Volfenac Retard last?

A: The prolonged-release tablet is typically associated with once-daily administration schedules. This formulation is designed to provide sustained pain relief and maintain consistent therapeutic levels of the drug over a 24-hour period.

Q: What are the most common side effects of Volfenac Retard?

A: According to official regulatory documents, the most common side effects include nervous system effects such as headache, dizziness, and vertigo. Gastrointestinal issues such as nausea, dyspepsia (indigestion), and abdominal pain are also frequently reported.

Q: Does Volfenac Retard cause stomach issues, and is there a way to avoid them?

A: This medication carries a documented risk of serious gastrointestinal adverse events, including bleeding and ulceration. The official administration guidelines suggest taking the tablet with or immediately after food, as this may help minimize potential gastrointestinal discomfort.

Q: Are there any signs that Volfenac Retard might be harming my liver?

A: Liver (hepatic) injury is listed as a serious, documented risk associated with the use of this medication. Signs that may indicate a concern include nausea, unusual fatigue, jaundice (yellowing of the skin or eyes), and flu-like symptoms. Official safety information notes that monitoring of liver function is generally performed during treatment.

Q: What should I do if I forget to take my dose of Volfenac Retard?

A: Official administration guidance confirms that if a dose is missed, regulatory procedure advises taking the subsequent dose at the regular scheduled time. It strongly cautions against doubling the dose to make up for a dose that was skipped.

Q: Why do doctors prescribe the 'retard' (sustained-release) version?

A: Healthcare professionals may prescribe the sustained-release formulation because it helps maintain more stable and consistent concentrations of the active ingredient in the bloodstream. This consistent profile is often beneficial for managing chronic conditions that require continuous pain and inflammation relief.

Q: How does the sustained-release mechanism of Volfenac Retard work?

A: The sustained-release feature is achieved through the tablet's specialized design, often involving a physical matrix or coating. This mechanism controls the rate at which the active ingredient dissolves and is absorbed by the body, ensuring a slow and steady release over several hours.

Q: Is Volfenac Retard a strong painkiller?

A: Volfenac Retard contains diclofenac, an NSAID (Non-Steroidal Anti-Inflammatory Drug) clinically recognized for its anti-inflammatory and potent pain-relieving effects.

Q: Can Volfenac Retard be used for all kinds of joint pain?

A: Official prescribing information indicates labeled use for the management of signs and symptoms related to specific conditions, primarily including chronic joint conditions like osteoarthritis and rheumatoid arthritis.

Q: Is it normal to feel tired after taking Volfenac Retard?

A: Somnolence, which refers to drowsiness or fatigue, is listed in regulatory documents as a documented, though rare, side effect of the medication. This adverse reaction is documented in the product safety information.

Q: Can Volfenac Retard affect your blood pressure?

A: The drug may interact with certain blood pressure medications, such as ACE inhibitors and diuretics, potentially reducing their effectiveness. Furthermore, hypertension (high blood pressure) is itself a documented possible side effect listed in official safety warnings.

Q: Is Volfenac Retard safe for older adults?

A: Official guidance notes that while routine dose adjustment is not always necessary for older adults, the lowest effective dose should be used for the shortest possible duration. Official regulatory warnings emphasize that older adults are at a higher documented risk for serious adverse events, particularly related to gastrointestinal issues and renal impairment.

Q: Is there a maximum amount of time you should take Volfenac Retard for?

A: Regulatory guidance emphasizes that the medication should be used for the shortest duration necessary for all patients. This principle is aligned with using the lowest effective dose, due to documented risks associated with longer-term use of NSAIDs.

Q: Is Volfenac Retard addictive?

A: Volfenac Retard contains diclofenac, which is not classified as a controlled substance in major regulatory jurisdictions. It is not considered an addictive or habit-forming medication.

Q: Can Volfenac Retard affect my ability to drive or operate machinery?

A: The medication may cause common side effects such as dizziness, vertigo, and drowsiness (somnolence). Official labeling advises that patients should exercise caution if engaging in activities that require full mental alertness, such as driving, due to these potential effects.

Q: Does Volfenac Retard help with fever?

A: As a Non-Steroidal Anti-Inflammatory Drug (NSAID), Volfenac Retard exhibits antipyretic properties. This means the medication can help reduce fever, in addition to its primary effects on pain and inflammation.

Q: Can Volfenac Retard make you feel dizzy?

A: Yes, dizziness and vertigo are listed in official regulatory documents as common adverse reactions experienced by patients taking this medication.

Q: Does Volfenac Retard affect sleep?

A: Somnolence (drowsiness) is documented as a rare side effect. This suggests a potential, though uncommon, influence on the patient's sleep-wake cycle.

Q: What kind of research supports the use of Volfenac Retard for arthritis?

A: The official uses for conditions like osteoarthritis (OA) and rheumatoid arthritis (RA) are supported by data from clinical studies. This evidence base includes rigorous clinical studies, such as randomized controlled trials and systematic reviews, which assess patient-reported outcomes related to discomfort and physical function.

Q: Can Volfenac Retard cause an allergic reaction, and what does that look like?

A: Yes, allergic reactions (hypersensitivity) are documented risks. These can range from mild symptoms like rash to severe, rare reactions such as anaphylaxis. Severe symptoms may include difficulty breathing, swelling of the face or throat, and widespread hives.

Q: Is Volfenac Retard a treatment for muscle spasms?

A: The official indication of the medication is for the relief of pain and inflammation associated with musculoskeletal and joint conditions. While it is not formally indicated as a muscle relaxant, its strong pain-relieving effects may help alleviate discomfort related to muscle issues.

Q: Can Volfenac Retard make existing kidney issues worse?

A: Severe kidney (renal) failure is a contraindication for use. Official safety information confirms that the drug can increase the risk of renal impairment, especially in patients who already have existing kidney issues, are elderly, or are volume-depleted.

Q: Are there known cases of Volfenac Retard causing mood changes?

A: Although not a common issue, official safety documentation lists psychiatric effects, such as disorientation and very rare cases of psychotic reactions. The product safety documentation lists these potential psychiatric effects.

Q: Can Volfenac Retard be used for headaches or migraines?

A: Diclofenac is documented in official labeling in some formulations as an approved treatment for acute migraine attacks. Its general indication for pain relief also applies to tension headaches.

Q: How is Volfenac Retard eliminated from the body?

A: The drug is primarily metabolized (broken down) in the liver. Following this, the components are rapidly and completely eliminated from the body, mostly via the kidneys (urine) and partly through the bile (feces).

Q: What are the signs of taking too much Volfenac Retard?

A: While there is no single typical clinical picture of overdose, regulatory documents state that symptoms may include gastrointestinal issues, vomiting, stomach bleeding, drowsiness, and headache. In rare instances, more severe effects like convulsions are possible.

Q: Is Volfenac Retard used for inflammation that isn't painful?

A: Yes, the fundamental purpose of this medication is to alleviate symptoms by mitigating the core biological processes of both pain and inflammation. Its anti-inflammatory effect is independent of whether the inflammation is currently causing a noticeable level of pain.

Advertisements

How should Volfenac Retard be stored and disposed of?

How to Store and Dispose of Volfenac Retard

The storage and disposal of Volfenac Retard (Diclofenac Sodium prolonged-release tablets) must comply with official regulatory mandates to maintain the product's stability and integrity.


Storage Requirements

Storage must occur at a temperature below 25°C (77°F). The medicine must be protected from moisture and heat by keeping it in a dry place and remaining in the original container. It is explicitly required that the tablets be kept out of the sight and reach of children.


Disposal Instructions

Disposal of unused or expired tablets must be completed in accordance with local requirements. The product must not be disposed of in wastewater (e.g., sink or toilet) or household trash to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Volfenac Retard found in:

A-Z Index: